NCT00880334 - Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC | Biotech Hunter

Enrollment

149

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

December 31, 2013

Study Completion Date

May 31, 2015

Conditions

Transitional Cell CarcinomaBladder Cancer

Interventions

DRUG

Docetaxel

Given intravenously on Day 1 of each 21-day cycle

DRUG

vandetanib

taken orally once a day, every day

DRUG

Placebo

Taken orally once a day every day

Trial Locations (3)

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston